Research

With over three decades of experience, Central Florida Retina is proud to be leading the way in the latest and most innovative treatments of retina and vitreous diseases.

Clinical Trials & You

Doctor at monitor with retina images

What is A Clinical Trial?

A clinical trial is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the safest and fastest way to find treatments that work in people and new ways to improve health.

Who Should Consider Clinical Trials?

Some people participate in clinical trials because they have exhausted standard (approved) treatment options. These options either did not work for them or they were unable to tolerate certain side effects. Clinical trials may provide another option when standard therapy has failed.

How is a Clinical Trial Conducted?

An agreement form is provided to you and explains what the study involves. It is also reviewed with you by members of the research department. Being in a study is completely voluntary, and you can change your mind at any time even if you have already signed the consent form.


Man getting eye exam

Contact The Research Department

For more info or to learn about how to enroll in one of our future studies, please fill out the form below. Thank you!

CFR Research Department
clinicalresearch@cfretina.com
800.255.7188


Current Clinical Trials

Diabetic Retinopathy

Help advance research on how to treat early diabetic retinopathy

What Is The Study About?

The study is being done to find out more information on whether a pill taken daily by mouth can slow or prevent the worsening of diabetic retinopathy.

Who Can Participate?

  • Adults age 18 to 80 with diabetic retinopathy.
  • Able to attend visits with the study eye doctor for the next four years.

Why Participate?

  • You will contribute to a better understanding of this disease and treatment.
  • You will add to new knowledge that may help others in the future.
  • The study medication is provided at no cost, and participants receive gift cards at each study visit.

Interest?

Contact the study coordinator (below) to find out more information and reference “DRCR Protocol AF.”

Contact: Ginny Bell, CRC

Phone: 407-425-7188

Address: 3824 Oakwater Circle, Orlando, Florida 32806

Email: vbell@cfretina.com

Living with Vision Loss Due to Neovascular (wet) Age-Related Macular Degeneration (AMD)?

We are looking for people to take part in a clinical research study to help us learn more about an investigational medication for Neovascular (web) age-related macular degeneration (AMD). The investigational medication has been designed to work differently from currently available treatments. We are trying to find out if the investigational medication may result in an improvement of vision.

Are you able to help?

You (or someone you know) may be able to take part in the COAST Study if you:

  • are at least 50 years of age
  • have been diagnosed with, or experience symptoms of, wet AMD
  • have not yet received any treatments for your wet AMD

The study will last just under 2 years (102 weeks) and will require regular visits to our study center. Your health will be monitored carefully by a team of doctors and nurses throughout the day. All study-related medications and assessments will be provided at no cost to you.

Please contact the study team today if you have questions or are interested in joining COAST Study. You are under no obligations to take part in the study. Let us help you get started today.

Clinical Research Department at Central Florida Retina 407-425-7188 (ext 1113)


Past Clinical Trials

Wet Age-Related Macular Degeneration

Regeneron

A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration

Alcon

A Phase III study randomized, parallel-group, multicenter, double-masked study of the safety and efficacy of Anecortave Acetate for Depot Suspension (15mg and 30 mg) versus sham administration in arresting the progression of non-exudative (dry) AMD in patients who are at risk for progressing to exudative (wet) AMD.

Retinal specialist with patient

Ophthotech

A Phase I Single Ascending Dose Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile Of Intravitreous Injections Of E10030 (Anti-Pdgf Pegylated Aptamer) Monotherapy And Of E10030 Given In Combination With Lucentis 0.5mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Sirion

A Phase II Multicenter, Randomized, Double-Masked, Placebo Controlled, Dose- Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

Genentech & Novartis SAILOR

A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

VERTACL

A Phase II/III Multi-Center, Randomized, Clinical Trial to evaluate the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants with neovascular Age-Related Macular Degeneration (AMD)

Genentech ANCHOR

A Phase IIIstudy which compares efficacy of subjects who have Lucentis®, injected into the eye once a month for two years, to PDT (Visudyne®), administered to the eye every three months for two years. in patients with wetAge-related Macular Degeneration (AMD)

NEI (SCORE)

Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion

Diabetic Macular Edema

Alimera (FAME)

A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/day and ASI-001B 0.2 μg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema

DRCR

A Phase II study for evaluation of Anti-VEGF therapy, Bevacizumab (Avastin) Intravitreal injections in Subjects with Diabetic Macular Edema

Partner Logos
WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.